Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven and KU Leuven) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre/i+12) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (Antwerp University Hospital) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J (Dana-Farber Cancer Institute) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Deaprtament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO Open, Vol. 2 (november 2017)  
2.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Czech Republic)) ; Van Cutsem, E. (KU Leuven. University Hospitals Leuven (Belgium)) ; Yoshino, T. (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hungary)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; Garcia-Carbonero, R. (Hospital Universitario Doce de Octubre) ; Ciuleanu, T. (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Maraňón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, S. (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of Oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  
3.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Roselló, S (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.